-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $45

Benzinga·08/05/2026 14:58:07
Listen to the news
Wells Fargo analyst Benjamin Burnett maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $47 to $45.